Literature DB >> 19185849

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.

David A Guertin1, Deanna M Stevens, Maki Saitoh, Stephanie Kinkel, Katherine Crosby, Joon-Ho Sheen, David J Mullholland, Mark A Magnuson, Hong Wu, David M Sabatini.   

Abstract

mTOR complex 2 (mTORC2) contains the mammalian target of rapamycin (mTOR) kinase and the Rictor regulatory protein and phosphorylates Akt. Whether this function of mTORC2 is critical for cancer progression is unknown. Here, we show that transformed human prostate epithelial cells lacking PTEN require mTORC2 to form tumors when injected into nude mice. Furthermore, we find that Rictor is a haploinsufficient gene and that deleting one copy protects Pten heterozygous mice from prostate cancer. Finally, we show that the development of prostate cancer caused by Pten deletion specifically in prostate epithelium requires mTORC2, but that for normal prostate epithelial cells, mTORC2 activity is nonessential. The selective requirement for mTORC2 in tumor development suggests that mTORC2 inhibitors may be of substantial clinical utility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19185849      PMCID: PMC2701381          DOI: 10.1016/j.ccr.2008.12.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  55 in total

Review 1.  The TOR pathway: a target for cancer therapy.

Authors:  Mary-Ann Bjornsti; Peter J Houghton
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  Genetic background controls tumor development in PTEN-deficient mice.

Authors:  Dan Freeman; Ralf Lesche; Nathalie Kertesz; Shungyou Wang; Gang Li; Jing Gao; Matthias Groszer; Hilda Martinez-Diaz; Nora Rozengurt; George Thomas; Xin Liu; Hong Wu
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

4.  Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.

Authors:  Jennifer E Skeen; Prashanth T Bhaskar; Chia-Chen Chen; William S Chen; Xiao-ding Peng; Veronique Nogueira; Annett Hahn-Windgassen; Hiroaki Kiyokawa; Nissim Hay
Journal:  Cancer Cell       Date:  2006-10       Impact factor: 31.743

5.  SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.

Authors:  Estela Jacinto; Valeria Facchinetti; Dou Liu; Nelyn Soto; Shiniu Wei; Sung Yun Jung; Qiaojia Huang; Jun Qin; Bing Su
Journal:  Cell       Date:  2006-09-07       Impact factor: 41.582

6.  NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.

Authors:  Qunying Lei; Jing Jiao; Li Xin; Chun-Ju Chang; Shunyou Wang; Jing Gao; Martin E Gleave; Owen N Witte; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

7.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

8.  The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C.

Authors:  Valeria Facchinetti; Weiming Ouyang; Hua Wei; Nelyn Soto; Adam Lazorchak; Christine Gould; Carolyn Lowry; Alexandra C Newton; Yuxin Mao; Robert Q Miao; William C Sessa; Jun Qin; Pumin Zhang; Bing Su; Estela Jacinto
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

9.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.

Authors:  A Suzuki; J L de la Pompa; V Stambolic; A J Elia; T Sasaki; I del Barco Barrantes; A Ho; A Wakeham; A Itie; W Khoo; M Fukumoto; T W Mak
Journal:  Curr Biol       Date:  1998-10-22       Impact factor: 10.834

Review 10.  Targeting the mTOR signaling network in cancer.

Authors:  Gary G Chiang; Robert T Abraham
Journal:  Trends Mol Med       Date:  2007-10-01       Impact factor: 11.951

View more
  195 in total

1.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

2.  Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.

Authors:  Kangdong Liu; Chanmi Park; Shengqing Li; Ki Won Lee; Haidan Liu; Long He; Nak Kyun Soung; Jong Seog Ahn; Ann M Bode; Ziming Dong; Bo Yeon Kim; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-04-24       Impact factor: 4.944

Review 3.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

4.  TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion.

Authors:  Samy Lamouille; Erin Connolly; James W Smyth; Rosemary J Akhurst; Rik Derynck
Journal:  J Cell Sci       Date:  2012-03-07       Impact factor: 5.285

Review 5.  Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Rik Derynck
Journal:  Cells Tissues Organs       Date:  2010-11-02       Impact factor: 2.481

6.  Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.

Authors:  Nicole D Facompre; Indu Sinha; Karam El-Bayoumy; John T Pinto; Raghu Sinha
Journal:  Int J Cancer       Date:  2012-03-20       Impact factor: 7.396

7.  A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Authors:  Andrew J Armstrong; George J Netto; Michelle A Rudek; Susan Halabi; David P Wood; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M De Marzo; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 8.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

9.  Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.

Authors:  Tomoyo Okada; Ann Y Lee; Li-Xuan Qin; Narasimhan Agaram; Takahiro Mimae; Yawei Shen; Rachael O'Connor; Miguel A López-Lago; Amanda Craig; Martin L Miller; Phaedra Agius; Evan Molinelli; Nicholas D Socci; Aimee M Crago; Fumi Shima; Chris Sander; Samuel Singer
Journal:  Cancer Discov       Date:  2016-08-30       Impact factor: 39.397

10.  mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Authors:  David R Driscoll; Saadia A Karim; Makoto Sano; David M Gay; Wright Jacob; Jun Yu; Yusuke Mizukami; Aarthi Gopinathan; Duncan I Jodrell; T R Jeffry Evans; Nabeel Bardeesy; Michael N Hall; Brian J Quattrochi; David S Klimstra; Simon T Barry; Owen J Sansom; Brian C Lewis; Jennifer P Morton
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.